New immunisation reference page: Neutropenia: Vaccine recommendations for children with chronic neutropenia
Children with neutropenia are at increased risk of bacterial and fungal infections and therefore preventing infections in this group is a priority in order to protect these children against vaccine preventable diseases (VPDs). However, this patient group is not addressed in The Australian Immunisation Handbook.
Our new reference page, Neutropenia: vaccine recommendations for children with chronic neutropenia discusses the recommendations for this group based on international guidelines and local consensus.
Để đọc thêm theo liên kết dưới đây:
MVEC: New immunisation reference page: Neutropenia: Vaccine recommendations for children with chronic neutropenia
TGA Provisional Approval of Moderna COVID-19 vaccine to include 12-17 years age group
On September 4 2021, the Therapeutic Goods Administration (TGA) granted provisional approval to Moderna Australia Pty Ltd for its COVID-19 vaccine—Spikevax (elasomeran) to include the 12-17 years age group. This decision follows the provisional approval granted by the TGA to Spikevax on 9 August 2021 for use in individuals aged 18 years and older.
To find out more information, please refer to our dedicated MVEC Moderna COVID-19 vaccination page in the link below:
MVEC Moderna COVID-19 vaccination page
New immunisation reference page: Immune thrombocytopenia (ITP)
Immune thrombocytopenia, also previously known as idiopathic thrombocytopenia purpura (ITP), is an uncommon autoimmune condition in which the body’s own immune system attacks platelets (the cells found in the blood which normally help the blood to clot).
Our new reference page discusses the background of ITP, including presentation of the condition and the association between ITP and MMR vaccines. Our page also answers questions around ITP and COVID-19 vaccines, including whether or not COVID-19 vaccines should be administered to people with a history of ITP.
Để đọc thêm theo liên kết dưới đây:
MVEC: Immune thrombocytopenia (ITP)
MVEC animation: Myocarditis, pericarditis and COVID-19 vaccines
MVEC have created a new animation to help explain myocarditis and pericarditis which have been reported in a small number of individuals who have received mARN Các loại vắc-xin phòng ngừa covid-19 Comirnaty™ Và Moderna.
To view the animation and to find out more information, please refer to our myocarditis, pericarditis following COVID-19 mRNA vaccines immunisation reference page:
MVEC animation: Myocarditis and pericarditis following COVID-19 mRNA vaccines
Câu hỏi thường gặp về vắc-xin COVID-19: sức khỏe phụ nữ
Chúng tôi đã mở rộng các Câu hỏi thường gặp về vắc-xin COVID-19 để bao gồm một phần dành riêng cho sức khỏe phụ nữ.
Để xem các câu hỏi thường gặp về vắc-xin COVID và lập kế hoạch mang thai, mang thai, cho con bú và kinh nguyệt, vui lòng theo liên kết bên dưới:
MVEC: Câu hỏi thường gặp về vắc-xin COVID-19: sức khỏe phụ nữ
Cập nhật trang tham khảo tiêm chủng: Chứng sợ kim tiêm
Gần đây, chúng tôi đã cập nhật trang ám ảnh về kim tiêm để bao gồm các thông tin và tài nguyên mới nhất có sẵn để giải quyết chứng sợ kim tiêm.
Trang của chúng tôi bao gồm thông tin và chiến lược dành cho các nhà cung cấp dịch vụ chăm sóc sức khỏe, cá nhân và người chăm sóc để quản lý chứng sợ kim tiêm và tiêm chủng.
Để xem trang này, vui lòng bấm vào liên kết sau:
SAEFVIC Rapid report: a new reporting pathway for COVID-19 vaccine AEFI
Reporting adverse events following immunisation (AEFI) is not mandatory in Victoria, however doing so allows the rapid investigation of any potential vaccine or system problems. This helps to ensure a safe and effective immunisation program and it maintains community confidence in vaccines.
The new SAEFVIC Rapid reporting pathway has been launched for reporting any common or expected side effects following a COVID-19 vaccine. Reporting via this pathway will not result in follow up of clinical symptoms however it will contribute to data collection and assist health authorities to understand the frequency of symptoms occurring. Should the vaccinee experience significant side effects, completing the SAEFVIC Extended report is recommended.
For more information on SAEFVIC, symptoms that should be reported, and instructions on how to report, please visit our immunisation reference page below:
MVEC: Surveillance of Adverse Events Following Vaccination in the Community (SAEFVIC)
Updated immunisation reference page: Vaccine confidence
We have recently updated our Vaccine confidence immunisation reference page to include the latest information and resources available to help address people’s questions and concerns about vaccines.
Our page includes information on how to talk to people who have concerns about vaccines, how to tackle misinformation and how to be a vaccine champion in your workplace or community.
Để xem trang này, vui lòng bấm vào liên kết sau:
New immunisation reference page: Myocarditis and pericarditis following mRNA COVID-19 vaccines
Myocarditis is an inflammatory disease of the heart muscle, whilst pericarditis is an inflammatory disease of the lining of the heart muscle. They are rare conditions, most commonly associated with viral infections (including SARS-CoV-2) but can also be triggered by other factors such as medications and autoimmune conditions. Globally, an increased number of cases above an expected population rate of myocarditis and pericarditis have been reported in individuals who have received mRNA COVID-19 vaccines (eg. Comirnaty™ and Moderna).
Our new reference page discusses the temporal association of myocarditis and pericarditis with mRNA COVID-19 vaccination, symptoms, investigations, as well as the implications on future COVID-19 vaccination.
Để đọc thêm theo liên kết dưới đây:
MVEC: Myocarditis and pericarditis following mRNA COVID-19 vaccines
Trang tham khảo tiêm chủng mới: Vắc xin Moderna COVID-19
Sau thông báo của Chính phủ Úc rằng 25 triệu liều (cũng như các phiên bản cụ thể của biến thể bổ sung) vắc xin COVID-19 của Moderna, Elasomeran, đã được bảo đảm cho người dân Úc, vắc xin này đã được TGA cấp phép xác định tạm thời vào tuần trước.
Trang tham khảo mới của chúng tôi khám phá các thử nghiệm lâm sàng khác nhau liên quan đến Elasomeran, cũng như trình bày chi tiết dữ liệu về tính sinh miễn dịch, hiệu quả và độ an toàn hiện có của loại vắc xin này.
Để đọc thêm theo liên kết dưới đây:
MVEC: Vắc xin Moderna COVID-19